Lumateperone Safety and Tolerability in Schizophrenia: A Narrative Review

Schizophrenia remains challenging to manage, as most available antipsychotic medications alleviate symptoms but are associated with significant adverse effects such as weight gain, sedation, and extrapyramidal symptoms (EPS). Lumateperone, a recently approved antipsychotic, has attracted attention due to its unique pharmacological profile. In addition to modulating dopamine receptors, it also influences serotonin and glutamate neurotransmission, potentially addressing a broader spectrum of symptoms, including cognitive and social deficits. This narrative review synthesizes recent clinical evidence on lumateperone, evaluating study design, outcomes, and consistency across trials. Current findings suggest that lumateperone reduces core symptoms of schizophrenia while demonstrating a more favorable safety profile than many established antipsychotics. In particular, it appears to carry a lower risk of metabolic and motor side effects, which may support improved long-term adherence. Overall, this review aims to contextualize the emerging body of evidence and to evaluate the potential role of lumateperone, particularly for patients with inadequate response to conventional antipsychotics.